ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

GYRE vs WVE // GROSS PROFIT MARGIN

Gyre Therapeutics Inc. (NASDAQ) VS. Wave Life Sciences Inc. (NASDAQ) • 15-METRIC TALLY: GYRE 6 — WVE 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GYRE VS. WVE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC GYRE WVE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE 95.40% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 25.40% -35.00% +60.40 GYRE /roic <GO>
EV/EBITDA & P/E Valuation 53.3x — — TIE /valuation <GO>
Free Cash Flow Yield -0.03% — — TIE /fcf-yield <GO>
Operating Margin 9.90% -60.00% +69.90 GYRE /operating-margins <GO>
Net Profit Margin 8.50% -60.00% +68.50 GYRE /net-margins <GO>
Revenue Growth (YoY) 10.20% -60.50% +70.70 GYRE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 14.33 0.85 +13.48 GYRE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 2/9 +3.00 GYRE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 49.8 50.6 -0.80 WVE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 67.2x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $714.8M $715.9M -$1.2M WVE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR GYRE REV WVE REV GYRE GROSS % WVE GROSS % GYRE FCF WVE FCF
FY 2025 $116.6M $42.7M 95.4% — -$180.0K -$188.2M
FY 2024 $105.8M $108.3M 96.3% — -$6.0M -$152.0M
FY 2023 $113.5M $113.3M — — $25.9M -$19.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GYRE // BETA —
WVE // BETA —